Lafutidine (INN) is a second generation H2 receptor antagonist having multimodal mechanism of action. It is currently marketed in Japan (Stogar) China (Lemeiting) and India (Lafaxid) It not only suppresses gastric acid secretion but also has cytoprotective properties by the virtue of its property to induce the collagen synthesis in the gastric mucosa.
This page contains content from the copyrighted Wikipedia article "Lafutidine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
